Eiko LifeSciences to acquire 51% stake in SSM Formulations
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The companies aim to expand treatment options for millions living with metabolic disorders
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Expands bioprocessing footprint across Asia
Subscribe To Our Newsletter & Stay Updated